Tagged with R

Pharma Legal Handbook BIOSIMILARS AND BIOLOGICS in Panama are regulated by Law No. 419 of February 1, 2024, Executive Decree No. 95 of May 14, 2019.   1. Are biosimilar medicines considered the same as generic medicines in your country? No. Generic medicines are defined as medicines distributed or sold that are marked…

France With over 35 years of experience across major pharmaceutical markets, Corinne Blachier-Poisson, General Manager of Amgen France, she discusses Amgen France’s ambitions and the company’s pivotal role in shaping France’s life sciences ecosystem. Our strength lies in combining scientific rigour, industrial reliability, and collaboration to deliver lasting value for patients…

Taiwan Dr Chih-Kang Chiang, Director-General of the TFDA, shares how Taiwan is redefining regulation through science, transparency, and international collaboration. Combining his backgrounds in medicine, toxicology, and law, he leads efforts to strengthen patient safety, accelerate innovation in AI and regenerative medicine, and reinforce supply resilience. This conversation offers insight into…

France After two decades with AstraZeneca across Europe and the United States, Anne-Laure Dreno now leads the group’s French affiliate at a time of exceptional scientific and organisational momentum. In this conversation, she reflects on AstraZeneca France’s rapid growth, the country’s evolving research and access landscape, and the company’s pioneering commitment…

France Launched in 2022 under the France 2030 biocluster programme, the Paris-Saclay Cancer Cluster (PSCC) is rapidly positioning itself as a new epicentre for oncology innovation in Europe. Under the leadership of CEO Benjamin Garel, it brings together world-class hospitals, leading universities, and major pharmaceutical partners with the mission of transforming…

France Founded in 1973, IFIS stands at the intersection of education, industry, and public policy, shaping the capabilities that underpin France’s global health leadership. Evolving from its origins as a training fund manager into a multifaceted institution, IFIS today drives professional excellence across pharmaceuticals, medtech, and cosmetics, bridging technical expertise, digital…

China This week’s China healthcare highlights from PharmaBoardroom content partner Selesta include GSK’s $50M partnership with LTZ for myeloid cell engagers, Kind Pharma’s RMB 400M+ Series C for anemia and breast cancer programs, and Phrontline’s $60M funding to advance bispecific ADCs. Clinical breakthroughs feature BeOne’s zanidatamab + tislelizumab combo significantly improving…

Hong Kong GSK Hong Kong’s first year under Nicholas Teo marks a period of rapid evolution in the city’s healthcare system, from the strengthening of primary care to a deeper reliance on real world evidence and closer collaboration across government, academia and insurers. The affiliate is advancing a balanced portfolio in specialty…

Hong Kong With a strong heritage in Asia, DKSH has evolved into a leading force in connecting global healthcare innovation with local patient access. In this interview, Wai Ting Fong, VP Healthcare and Head Country Management at DKSH Hong Kong, shares how the organisation is shaping the region’s healthcare landscape, from pioneering…

USA John Murphy, III, president & CEO of the Association for Accessible Medicines (AAM) lays out a stark warning: the very medicines that keep the US healthcare system affordable and functioning are at risk. Generics and biosimilars fill nine out of ten prescriptions yet account for a tiny slice of spending,…

USA Michael Petroutsas, President and Head of Astellas Pharma US, reflects on the company’s ongoing transformation and the market’s growing strategic importance within Astellas’ global organisation. He goes on to highlight Astellas’ focused therapeutic portfolio in oncology and specialty medicine, investments in advanced modalities like gene and cell therapy, and commitment…

China This week’s China healthcare highlights from PharmaBoardroom content partner Selesta showcases strong innovation and global ambitions through major licensing deals, IPO activity, and clinical advancements. Notable transactions include Shimai Pharma’s Hong Kong IPO for its next-gen TCE platform, Mindray Medical’s IPO for global expansion, and transformative deals like Third Arc…